{"id":41886,"date":"2026-09-25T04:18:44","date_gmt":"2026-09-25T04:18:44","guid":{"rendered":"https:\/\/g-medtech.com\/news\/?p=41886"},"modified":"2026-09-25T04:23:30","modified_gmt":"2026-09-25T04:23:30","slug":"revvity-launches-ce-ivdr-certified-solution-for-early-detection-of-type-1-diabetes","status":"publish","type":"post","link":"https:\/\/g-medtech.com\/news\/revvity-launches-ce-ivdr-certified-solution-for-early-detection-of-type-1-diabetes\/","title":{"rendered":"Revvity Launches CE-IVDR-Certified Solution for Early Detection of Type 1 Diabetes"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/g-medtech.com\/database\/medtech-players\/index\/revvity\/\" target=\"_blank\" rel=\"noreferrer noopener\">Revvity<\/a> has announced the launch of the GSP T1D 3plex kit, a fully automated, CE-IVDR-certified multiplex autoantibody detection solution designed to enable population-wide screening programs that identify children at risk of developing type 1 diabetes before symptoms appear. The launch expands Revvity&#8217;s diagnostic offerings from newborn screening into early childhood screening.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Type 1 diabetes is often only identified after significant beta-cell damage has occurred, presenting first as a life-threatening diabetic ketoacidosis episode. Using capillary dried blood spots for simple, scalable sample collection, the 3-plex assay is processed on Revvity&#8217;s GSP instrument, a high-throughput platform already trusted in newborn screening. This end-to-end workflow, which includes reagents, instrumentation, and software, can detect at-risk individuals months or years before symptoms, enabling early intervention and disease-modifying treatment. The kit is designed to meet the needs of emerging national T1D screening programs, providing a reliable, regulatory-compliant solution.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The GSP T1D 3plex kit is the latest addition to Revvity&#8217;s expanding diabetes portfolio, which spans research, clinical testing, and service models. At the European Association for the Study of Diabetes in Milan from September 28 to October 2, Revvity will present details on both its T1D on-site installation and off-site testing service solutions developed in collaboration with Sanofi. The GSP T1D 3plex kit will initially be available in Europe and all markets that accept CE IVD-marked products. The GSP T1D 3plex is not a U.S. Food and Drug Administration-cleared device.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Anna Godenhjelm, Vice President and General Manager of Reproductive Health at Revvity, stated that the launch of the GSP T1D 3plex kit marks an important step forward for Revvity&#8217;s expansion into child health screening. Godenhjelm noted that the milestone demonstrates how the company&#8217;s expertise in newborn screening can be leveraged to advance earlier detection in new areas of healthcare.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Revvity has launched the GSP T1D 3plex kit, a fully automated, CE-IVDR-certified multiplex autoantibody detection solution using dried blood spots for scalable sample collection, designed to enable population-wide screening programs that identify children at risk of type 1 diabetes before symptoms appear.<\/p>\n","protected":false},"author":2,"featured_media":41888,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"colormag_page_layout":"default_layout","footnotes":""},"categories":[488,6,675,25],"tags":[704,755],"class_list":["post-41886","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","category-europe","category-ivds","category-products-technologies","tag-ce-mark","tag-diabetes"],"_links":{"self":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts\/41886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/comments?post=41886"}],"version-history":[{"count":0,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts\/41886\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/media\/41888"}],"wp:attachment":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/media?parent=41886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/categories?post=41886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/tags?post=41886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}